Actively managed fund

AXA Framlington Biotech Fund - Z Acc

ISIN
GB00B784NS11
Minimum investment
100,000 GBP

How good is this fund, really?

See the rating in the app

About AXA Framlington Biotech Fund - Z Acc

Biotechnology, genomics and medical research companies account for at least 80% of AXA Framlington Biotech Fund. Holdings can be of any size and based anywhere, though the portfolio leans towards the US because that is where most biotech firms are. The goal is long-term capital growth over five years or more, pursued through active stock picking by AXA Investment Managers UK based on financial analysis, management quality and growth prospects. The NASDAQ Biotechnology Index serves as a reference and a performance comparator. AXA's exclusion policies apply, removing among others companies with ESG scores below 1.43 out of 10. The Z accumulation unit class keeps income inside the fund and has ongoing charges of 0.82%. The fund was launched in 2001; the KIID suggests a minimum holding period of five years.

Watch this fund for free Add AXA Framlington Biotech Fund - Z Acc to your watchlist in the PowerFunds app and we tell you when it falls behind the rest of its category.

Watch the fund for free

Where to buy AXA Framlington Biotech Fund - Z Acc — platforms and fees

Sold on 4 platforms we follow.

AXA Framlington Biotech Fund - Z Acc — its category

Sector Equity Biotechnology — PowerFunds rates 55 funds in this category every month.

Biotechnology funds →

Other funds